本帖最后由 老马 于 2012-1-13 21:20 编辑 1 l* W9 w! t) s5 L4 a
, z9 S5 A8 T7 V/ } H, v
爱必妥和阿瓦斯丁的比较
" d/ Q& x8 U9 _! a0 m
# r% L3 D- ^9 K- l; U" S
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ D: O$ \/ L# ?1 L _0 ~
7 k \. S D2 m+ b8 L
" G5 s' g" c4 {* Y0 @
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 |! B4 g0 E! ~( R) b==================================================
# w5 _' V! d9 @1 n2 N8 Y+ KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 p+ b" j$ E/ M% Q" r% y( Q4 ^" i
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* y. ?# y2 d/ [4 CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ }0 o' l Y+ y2 J9 v" H6 o! d
|